Internal Medicine, Hematology & Oncology · Denver, CO
NPI
1447665906
Since 2014
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1721 E 19th Ave Ste 300
Denver, CO, 80218
Phone (720) 754-4800
Groups this clinician bills Medicare through
Medicare paid, 2024
$417K
23,768 services
Medicare patients, 2024
256
Average age 72
Drug cost, 2024
$3.5M
1,241 prescriptions
Company payments, 2025
$898
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Luke J Mountjoy was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 3,960 times for 17 patients. In total Luke J Mountjoy billed 23,768 services in 78 codes, and Medicare paid $417K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 3,960 | 17 | $38.60 | $153K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 610 | 11 | $36.24 | $22K |
| 36415 Venipuncture Blood Collection | Office | 538 | 97 | $8.65 | $4,654 |
| J3475 Injection, magnesium sulfate, per 500 mg | Office | 408 | 25 | $0.48 | $198 |
| 99215 Office E&M - Established | Office | 254 | 98 | $132.44 | $34K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 224 | 16 | $0.07 | $16.4 |
| 96366 Intravenous Infusion, Hydration | Office | 89 | 36 | $15.75 | $1,402 |
| 96365 Intravenous Infusion, Hydration | Office | 73 | 47 | $48.82 | $3,564 |
| 96401 Chemotherapy Administration | Office | 58 | 36 | $55.94 | $3,245 |
| 99205 Office E&M - New | Office | 45 | 45 | $155.05 | $6,977 |
| 96375 Injection Administration | Office | 45 | 23 | $11.90 | $536 |
| 96413 Chemotherapy Administration | Office | 42 | 24 | $101.09 | $4,246 |
| 96372 Injection Administration | Office | 23 | 20 | $11.05 | $254 |
By year: 2022 $617K for 25,574 services; 2023 $450K for 20,809 services; 2024 $417K for 23,768 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 538 | 97 | $8.65 | $4,654 |
Medicare prescription drug claims, 2024
In 2024, the drug Luke J Mountjoy prescribed most often to Medicare patients was Acyclovir, with 139 prescriptions and refills. In total Luke J Mountjoy wrote 1,241 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 139 | 214 | 43 | $2,309 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 97 | 123 | 33 | $411 |
| Valacyclovir Valacyclovir Hcl | 85 | 114 | 22 | $6,587 |
| Jakafi Ruxolitinib Phosphate | 81 | 81 | 17 | $1.2M |
| Prednisone Generic | 35 | 45 | 20 | $251 |
| Prevymis Letermovir | 32 | 32 | 11 | $251K |
| Eliquis Apixaban | 29 | 39 | Under 11 | $21K |
| Lenalidomide Generic | 27 | 27 | Under 11 | $408K |
| Hydrocortisone Generic | 26 | 30 | Under 11 | $733 |
| Dexamethasone Generic | 24 | 24 | 16 | $482 |
| Tasigna Nilotinib Hcl | 23 | 27 | Under 11 | $330K |
| Omeprazole Generic | 23 | 47 | Under 11 | $196 |
| Pantoprazole Sodium Generic | 22 | 46 | 12 | $162 |
| Posaconazole Generic | 20 | 20 | 11 | $19K |
| Tacrolimus Generic | 20 | 26 | Under 11 | $1,828 |
Brand drugs: - claims; generic drugs: 845 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Luke J Mountjoy $898 ($348 in general payments such as food, travel and fees and $550 for research) from 10 companies. The largest payer was Eli Lilly and Company with $550.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.